12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Company News  |  Deals

Allergan, Spectrum Pharmaceuticals deal

Spectrum reacquired from Allergan rights to develop and commercialize apaziquone in the U.S., EU and other territories. In exchange, Allergan is eligible for undisclosed, single-digit royalties. In 2008, Spectrum granted Allergan exclusive, worldwide rights, excluding Asia, to develop and commercialize the compound, an analog of...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >